Long-Term GLP-1 Maintenance

STEP-4 — what happens when semaglutide is stopped

STEP-4 was a 68-week trial designed to test maintenance. All participants received semaglutide 2.4 mg for an initial 20-week run-in. Those who completed run-in were then randomized 2:1 to continue semaglutide or switch to placebo for the remaining 48 weeks¹.

Results: participants continuing semaglutide lost an additional 7.9% of body weight (cumulative loss 17.4% from baseline). Participants switched to placebo regained 6.9%, ending at a cumulative loss of 5.0% from baseline. The treatment difference at the end of the maintenance phase was 14.8 percentage points.

The pattern is clear: GLP-1 produces continued benefit with continued use, and discontinuation reverses much of the gain. This is consistent with the underlying biology of obesity, which involves persistent dysregulation of appetite, energy expenditure, and metabolic adaptation that does not normalize with weight loss alone.

SURMOUNT-4 — same pattern with tirzepatide

SURMOUNT-4 used a similar design with tirzepatide. After 36 weeks of run-in (during which mean weight loss was 20.9%), participants were randomized to continue tirzepatide or switch to placebo for an additional 52 weeks. Continuers lost an additional 5.5%; placebo switchers regained 14.0%².

By trial end, continued-tirzepatide participants had cumulative weight loss of 25.3% from baseline, while placebo-switched participants had only 9.9%. The dramatic regain after discontinuation parallels STEP-4 and supports the chronic-disease framing across the entire GLP-1 class.

Why does weight return after stopping?

Several mechanisms contribute to post-GLP-1 regain. Appetite signaling rebounds: hunger hormones (ghrelin) return to elevated levels and satiety hormones (PYY, leptin) decrease as fat mass shrinks. Resting energy expenditure decreases in proportion to lean mass loss and stays below baseline. Food reward signaling, suppressed by GLP-1, recovers within weeks of discontinuation³.

These changes are predictable from the obesity homeostasis literature and would be expected with any weight-loss intervention. Bariatric surgery is the only treatment that produces durable weight loss WITHOUT continued pharmacotherapy in most patients — and even bariatric surgery patients regain 15% to 25% of lost weight over 5 to 10 years if not maintained with lifestyle.

The implication is not that GLP-1 has failed if regain occurs upon discontinuation — it is that discontinuation is the equivalent of stopping an antihypertensive: predictable return of the underlying condition.

Dose tapering strategies

When patients want to reduce or stop GLP-1 therapy, several tapering approaches have been used clinically. Direct discontinuation (stopping abruptly) leads to gradual regain over weeks to months. Dose reduction (e.g., from 2.4 mg to 1.7 mg or 1.0 mg semaglutide) may preserve some weight loss while reducing cost and side effects.

Dose-extension tapering (e.g., taking the medication every 10 days instead of every 7) may preserve receptor activation while reducing total monthly drug exposure. This strategy is not supported by formal trial evidence but is used clinically when patients want to reduce frequency.

Maintenance dose for long-term use is generally 1.0 to 2.4 mg semaglutide weekly or 5-15 mg tirzepatide weekly, depending on patient response and tolerability. Some patients achieve adequate maintenance at lower doses than those used for active weight loss.

Lifestyle integration

Lifestyle modification (nutrition, physical activity, sleep, stress management) does not replace GLP-1 therapy in established obesity, but it amplifies and sustains the benefit. Patients who maintain adequate physical activity preserve more lean mass during weight loss; those with stable sleep maintain better appetite regulation; those with structured nutrition habits maintain weight more reliably during dose reductions.

Programs that combine GLP-1 therapy with intensive behavioral support produce greater weight loss than GLP-1 alone (STEP-3 demonstrated 16.0% weight loss with intensive behavioral therapy + semaglutide versus 14.9% with semaglutide and standard lifestyle support).

Resistance training during weight loss is particularly important. Weight loss is approximately 70% fat and 30% lean mass without exercise; with adequate resistance training, the proportion shifts toward 80%/20% fat-to-lean ratio, preserving metabolic rate and physical function.

Cost and access — the maintenance question

Long-term GLP-1 therapy at current branded prices ($1,000+ per month) is financially out of reach for most patients without insurance coverage. Compounded versions ($145-$400 per month) make extended therapy more accessible. Patients should plan for the financial reality of long-term therapy when starting; abrupt discontinuation due to cost is a leading reason for weight regain in registry data.

Insurance coverage for maintenance GLP-1 therapy after weight goal is achieved is variable. Some plans approve initial weight-loss treatment but discontinue coverage once BMI threshold is no longer met (despite the regain risk). Patient and clinician advocacy for chronic-disease framing may help; documentation of regain risk and prior weight history strengthens prior-authorization renewals.

When discontinuation may be appropriate

Despite the regain risk, some patients may reasonably choose to discontinue GLP-1 therapy. Examples include: pregnancy planning (mandatory discontinuation per FDA labeling), intolerable persistent side effects despite dose adjustments, cost burden incompatible with continued use, achievement of weight goals plus successful adoption of substantial behavioral changes, or development of conditions for which alternative therapies are preferred.

Patients discontinuing should be counseled to expect 50% to 75% regain over 12-18 months unless behavioral changes and other supports are robust. Weight monitoring with willingness to restart GLP-1 if regain becomes substantial is a reasonable strategy. Some patients use 'pulsed' GLP-1 therapy (e.g., 6-month on, 3-month off cycles) — clinical data on this approach are limited.

Related editorial coverage

• STEP-1 trial: initial weight-loss outcomes
• Semaglutide peptide profile
• Tirzepatide peptide profile

Frequently asked questions

Will I gain the weight back if I stop semaglutide?

Most patients regain a substantial proportion of lost weight after discontinuing GLP-1 therapy. In STEP-4, participants switched to placebo regained 6.9% of body weight while continuers lost an additional 7.9%¹. The pattern is consistent across STEP-4, SURMOUNT-4, and observational data. Obesity is increasingly viewed as a chronic relapsing condition that requires ongoing treatment rather than a one-time intervention.

How long should I stay on semaglutide?

There is no fixed duration. For patients who tolerate the medication and achieve and maintain weight loss benefits, long-term continuation is increasingly the recommended approach. Some patients may use lower maintenance doses after reaching goal weight. The decision should be individualized based on weight stability, side effects, cost, and patient preference.

Can I lower my dose to maintain weight?

Many patients can maintain weight at lower doses than required for active loss. Common maintenance regimens: semaglutide 1.0 mg weekly (instead of 2.4 mg) or tirzepatide 5-10 mg weekly (instead of 15 mg). Trial evidence specifically for dose reduction maintenance is limited; this is a clinical strategy based on extrapolation.

Is GLP-1 a 'forever' medication?

For many patients with obesity, yes. The chronic-disease framing of obesity treats GLP-1 receptor agonists similarly to antihypertensives or statins — medications taken long-term to control an underlying condition rather than 'cured' over a fixed treatment course. The decision is individualized based on weight stability, lifestyle changes achieved, cost, and patient values.